Close Menu
  • Home
  • Identity
  • Inventions
  • Future
  • Science
  • Startups
  • Spanish
What's Hot

Fortinet releases patches for important SQL injection defects in Fortiweb (CVE-2025-25257)

YC Back Apolink by 19-year-old Bag $4.3 million to build a 24/7 connection for Leo satellite

Helios wants to be an AI operating system for public policy experts

Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise with Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • User-Submitted Posts
Facebook X (Twitter) Instagram
Fyself News
  • Home
  • Identity
  • Inventions
  • Future
  • Science
  • Startups
  • Spanish
Fyself News
Home » Nature’s answer to the fight against super bugs
Inventions

Nature’s answer to the fight against super bugs

userBy userFebruary 24, 2025No Comments7 Mins Read
Share Facebook Twitter Pinterest Telegram LinkedIn Tumblr Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

As the efficacy of antibiotics decreases, clinical trials are increasing. Cellexus is committed to supporting the development of phage therapy that uses bacteriophages to combat superbugs.

Antibiotics, including antibiotics, antivirals, antifungals and antiparasix are drugs used to prevent and treat infections in humans, animals and plants.

So-called superbugs are microorganisms, usually bacteria, that are resistant to one or more antibacterial agents previously used to treat them.

For almost 100 years, antibiotics have helped animals and humans live longer and healthier lives. The widespread and frequently inappropriate use of antibiotics has promoted significant and increased cases of multidrug resistant bacteria (AMR) overall.

It is estimated that 4.71 million deaths were associated with bacterial AMR in 2021. This includes 1.14 million deaths caused by bacterial AMR. By 2050 each year, ² has been presented as a major cause of human mortality.

The threat of AMR is not limited to human health, but it should be viewed in a broader, healthier context in which AMR affects the health and productivity of animals and crops. The impact of AMR is projected to cost 1tr by 2030 and by 2050 the world will lose 3.8% of GDP.

Antibiotics
Figure 1: The impact of AMR is important and broad

In 2015, the World Health Organization (WHO) committed to the Global Action Plan (GAP) to tackle AMR. From there, as of November 2023, 178 countries developed AMR National Action Plans (NAPS) in line with GAP. A key element of the plan is the development of new antibiotics, in which bacteriophages (also known as phages) are included as a highly promising solution.

What is phage?

Phages are viruses that target and kill bacteria, and are the most abundant organisms on the planet. Phages can be found in all natural environments, from human intestines to Antarctic soils. To put this in context, it is estimated that there are 1031 phage particles in the world with 200 million tons of biomass.

Each phage that evolves along with a bacteria is usually special to target a specific bacterial strain, and for each bacteria there are multiple phages that hunt it.

Bacteriophage
Figure 2: Life cycle of lysed bacteriophages

Phages hunt bacteria because they must replicate using bacterial cell machines. When the phage finds the target bacteria, it binds to the surface and injects the genetic material into the bacterial cells. It then hijacks the bacterial cell machine to create more phage particles that form until the bacteria burst, releasing a large number of phages to go hunting.

Phage therapy and challenge status

Despite being discovered and used as a therapeutic long before the discovery of antibiotics, phage therapy was largely discounted when antibiotics became available. Antibiotics outperformed phage therapy because they provided widespread infectious efficacy against a wide range of bacteria and were inexpensive and easily administered.

Now that antibiotics are losing effectiveness, the eyes are back to phage therapy as a solution. High-throughput laboratory techniques such as genetic sequencing and advanced bioinformatics are readily available, making preparation of safe and effective phage therapies easier to achieve. Over the past decade, the number of phage-based clinical trials has increased significantly, indicating a renewed interest in phages.

Nevertheless, many challenges remain, requiring coordinated efforts from a variety of stakeholders, not just researchers and clinicians, but also funders, regulatory agencies and governments. .

Phage
Figure 3: Number of clinical trials initiated by geographical regions. Data sources: www.clinicaltrials.gov and www.eudract.ema.europa.eu.

The development of tools to streamline phage isolation, analysis and production is essential for the broad implementation of phage therapy. At Cellexus, we are committed to providing phage scientists with the perfect cultural platform to overcome the unique challenge of producing phages and supporting the critical work of fighting AMR.

CellMaker systems offer outstanding performance and process benefits, focusing on three key aspects: resource utilization, regulatory compliance, and reliability.

resource

CellMaker is designed to make the most of the resources available (time, space, money).

Cell makers are ideal solutions for producing phages at very high titers (concentrations) and are 10-100 times higher and more frequently than can be achieved using other types of bioreactors. . The ability to generate phages with much higher titers reduces production costs by using smaller culture volumes. Additionally, generating phages at higher concentrations will remove and/or reduce costly and time-consuming downstream processing steps.

Higher yields provide highly effective gas and nutrient exchange to support bacterial growth, but mechanically associated with traditional bioreactors that can damage cells and phages as well. This is due to unique air-fuel mixing technology that does not have the power.

Patented cell manufacturer airborne bioreactors are single use and actually eliminate the risk of cross-contamination during cell culture processes and reduce the burden of process verification.

Figure 4: Cell makers are ready to put new bioreactor bags into cell maker enclosures, fill with media and shove GO, and produce something completely different within minutes!

Cell maker single-use bioreactors maximize laboratory productivity by minimizing turnaround times for bioreactors. A virtually turnkey solution, cell makers can be used in minutes and can disable cleaning, assembly and sterilization processes associated with reusable bioreactors, making them more sustainable It will be the solution.

In addition to time and money, space is usually a limiting factor within a cell culture suite. CellMaker is a small modular system that can be configured to fit in virtually any laboratory. A single controller allows you to control one or two 8L and/or 50L enclosures, providing scalability of 1.5L to 100L, requiring minimal lab space.

Regulations

Made from an ISO Class VII Cleanroom with ISO 13485:2016 verified and FDA 21 CFR 820 Compliant, the cell maker bioreactor bag provides the regulatory compliance required for rapid translation from research to therapeutic production. The ability to rapidly initiate the production of therapeutic phages is essential to effectively responding to the development of antibiotic-resistant pathogens.

Supporting the system’s operation is intuitive and highly usable cell maker software that provides complete control and cutting of the cell culture process. CellMaker software can operate in research mode or GMP manufacturing mode according to 21 CFR 11 Part 11.

Reliability

Cellmaker sets a new standard for bioreactor reliability. Repeated assembly and disassembly of a bioreactor is not only expensive, but can lead to container damage, seal failures, and process problems. CellMaker removes all sources of these potential batch failures. With few moving parts and no requirements for assembly or maintenance of the vessel, cell manufacturers are always ready to use. All cell manufacturers’ bioreactor bags are rigorously inspected and pressure tested after production, so you can rest assured that the cell manufacturer will not disappoint you.

Figure 5: Overview of cell manufacturer benefits

Lead the way

Cellexus is at the forefront of phage production technology and is developing a cell manufacturer platform to further support the rapidly evolving requirements of phage scientists. We always want to discuss specific requirements and work with our partners to overcome specific challenges. If you’d like to explore how cell makers can help you with your workflow, feel free to contact us.

reference

GBD 2021 antibiotic resistance collaborator. Global burden of bacteria antibiotic resistance 1990-2021: Systematic analysis with forecasts up to 2050. Lancet. 2024 Sep 28; 404 (10459): 1199-1226. doi: 10.1016/s0140-6736 (24) 01867-1. EPUB 2024 Sep16. PMID: 39299261; PMCID: PMC11718157. O’Neill, J. (2014) Antibiotic Resistance: An Attack on Crisis for National Health and Wealth. Antibacterial resistance review, 20, 1-16. World Bank – Jonas, A.B.; Irwin, A. ; Berthe, F., Cesar, J., Le Gall, F. G.; Marquez, p.v. (2017). Drug-resistant infections: Threats to our economic future (Volume 2): Final Report. HNP/Agriculture Global Antibacterial Resistance Initiative Washington, DC: World Bank Group. Chevallereaau, A., Pons, B.J., Van Houte, S. et al. (2022). Interactions between bacteria and phage communities in the natural environment. Nat Rev Microbiol 20, 49–62. https://doi.org/10.1038/S41579-021-00602-Y Strathdee, SA, Hatfull, GF, Mutalik, VK, Schooley, Rt. (2023) Phage therapy: From biological mechanisms to future directions. cell. January 5, 2023; 186(1): 17-31. doi: 10.1016/j.cell.2022.11.017. PMID: 36608652; PMCID: PMC9827498 Whitford, WG, Petrich, MA, Flanagan, WP. (2019). Environmental Impact of Single Use Systems, Disposable Techniques in Biopharmaceutical Manufacture, 2nd Edition, John Wiley & Sons, Inc.

This article will also be featured in the 21st edition of Quarterly Publication.


Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleIndia Kohli closes “outside noise” in the landmark century against Pakistan | Cricket News
Next Article Ukraine celebrates the third anniversary of the war with support plagued by uncertainty | Russia – Ukraine War News
user
  • Website

Related Posts

EV transitions face rocky paths to competitiveness

July 11, 2025

The US Agricultural Reserve is a large CO2 sink, according to research

July 11, 2025

EU material recovery rules to enhance waste batteries recycling

July 11, 2025
Add A Comment
Leave A Reply Cancel Reply

Latest Posts

Fortinet releases patches for important SQL injection defects in Fortiweb (CVE-2025-25257)

YC Back Apolink by 19-year-old Bag $4.3 million to build a 24/7 connection for Leo satellite

Helios wants to be an AI operating system for public policy experts

All stages in Boston and 4 days until lowest ticket prices disappear

Trending Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Please enable JavaScript in your browser to complete this form.
Loading

Welcome to Fyself News, your go-to platform for the latest in tech, startups, inventions, sustainability, and fintech! We are a passionate team of enthusiasts committed to bringing you timely, insightful, and accurate information on the most pressing developments across these industries. Whether you’re an entrepreneur, investor, or just someone curious about the future of technology and innovation, Fyself News has something for you.

ICEX Forum 2025 Opens: FySelf’s TwinH Showcases AI Innovation

The Future of Process Automation is Here: Meet TwinH

Robots Play Football in Beijing: A Glimpse into China’s Ambitious AI Future

TwinH: A New Frontier in the Pursuit of Immortality?

Facebook X (Twitter) Instagram Pinterest YouTube
  • Home
  • About Us
  • Advertise with Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • User-Submitted Posts
© 2025 news.fyself. Designed by by fyself.

Type above and press Enter to search. Press Esc to cancel.